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Natural killer (NK) cells are innate lymphoid cells, and
their presence within human tumors correlates with
better prognosis. However, themechanismsbywhich
NK cells control tumors in vivo are unclear. Here, we
used reflectance confocalmicroscopy (RCM) imaging
in humans and in mice to visualize tumor architecture
in vivo.Wedemonstrated that signaling via theNKcell
receptor NKp46 (human) and Ncr1 (mouse) induced
interferon-g (IFN-g) secretion from intratumoral
NK cells. NKp46- and Ncr1-mediated IFN-g produc-
tion led to the increased expression of the extracel-
lular matrix protein fibronectin 1 (FN1) in the tumors,
which alteredprimary tumor architecture and resulted
in decreasedmetastases formation. Injection of IFN-g
into tumor-bearingmiceor transgenicoverexpression
of Ncr1 in NK cells in mice resulted in decreased
metastasis formation. Thus, we have defined amech-
anism of NK cell-mediated control of metastases
in vivo that may help develop NK cell-dependent can-
cer therapies.
INTRODUCTION
NK cells are cytotoxic innate lymphoid cells (ILCs), which kill ma-
lignant cells (Elboim et al., 2010; Glasner et al., 2012a; Halftecket al., 2009; Koch et al., 2013; Morvan and Lanier, 2016), virus-
infected cells (Bar-On et al., 2013, 2014; Diab et al., 2016,
2017; Gazit et al., 2006; Glasner et al., 2012b, 2015a; Seidel
et al., 2012), bacteria (Chaushu et al., 2012; Gur et al., 2013a,
2015), and fungi (Vitenshtein et al., 2016) and also play a role in
autoimmunity (Gur et al., 2010, 2011, 2012, 2013b; Wensveen
et al., 2015), allergy (Ghadially et al., 2013), and graft-versus-
host disease (Ghadially et al., 2014). NK cell killing is executed
following engagement of activating receptors, which include,
among others, the natural cytotoxicity receptors (NCRs)
NKp30, NKp44, and NKp46 (Ncr1 in mice). Triggering of
NKp46 leads not only to perforin-mediated direct cytotoxicity,
but also to secretion of inflammatory cytokines, mainly IFN-g
and TNF-a (Morvan and Lanier, 2016).
Several pathogen-derived ligands have been identified for
NKp46 such as the influenza, Sendai, and Newcastle disease
hemaglutinins (HAs) (Draghi et al., 2007; Gazit et al., 2006;
Jarahian et al., 2009, 2011; Mandelboim et al., 2001), but the
identities of its membrane-bound cellular and tumor ligands
remain largely unknown. To study NKp46 and Ncr1 activity
in vivo, we generated an Ncr1 knockout (KO) mouse in which
Ncr1 was replaced by a green fluorescent protein (GFP) reporter
(Ncr1gfp/gfp) (Gazit et al., 2006). In the heterozygous Ncr1+/gfp
mice (which are immune competent, as one Ncr1 allele is still
present) and in the Ncr1-deficient mice, NK cells develop
normally (Gazit et al., 2006; Glasner et al., 2015b; Satoh-
Takayama et al., 2009; Sheppard et al., 2013). Using these
mice, we have demonstrated that Ncr1 is involved in tumor elim-
ination. Specifically, Ncr1 was shown to control the growth of
melanoma (Lakshmikanth et al., 2009), lymphoma (HalfteckImmunity 48, 107–119, January 16, 2018 ª 2017 Elsevier Inc. 107
et al., 2009), carcinoma (Glasner et al., 2012a), and carcinogen-
induced fibrosarcoma (MCA) (Elboim et al., 2010). However, the
mechanisms by which NK cells control tumor development and
metastases via Ncr1, in vivo, remain largely unknown.
NK cell control of tumor metastases is especially intriguing, as
the presence of NK cells within tumors is usually sparse
(Delahaye et al., 2011; Desbois et al., 2012). However, in their
absence, increased tumor growth and metastasis were
described (Morvan and Lanier, 2016) and the numbers of NK
cells in tumors correlates with better prognosis and less likeli-
hood to develop metastases (Delahaye et al., 2011).
Melanoma is a potentially deadly cutaneous malignancy.
Although its prevalence is much lower compared to other skin
neoplasms such as basal cell carcinoma and squamous cell car-
cinoma, it remains the leading cause of death from skin cancers
(Guy and Ekwueme, 2011). Although recent development in the
treatment of advanced-stage melanoma yielded substantial
improvement in survival (Breunis et al., 2008; Flaherty et al.,
2010; Parakh et al., 2017), disease prevention mainly by avoid-
ance of solar damage is still advocated. Yet in spite of increased
use of topical ultraviolet (UV) filters, melanoma incidence is
constantly on the rise (Arnold et al., 2014). Therefore, early diag-
nosis and rapid surgical removal of the tumors are critical.
Reflectance confocal microscopy (RCM) is a novel, non-inva-
sive imaging technique that permits real-time visualization of
cellular components in the skin at a resolution close to that of
conventional histology. A detailed description of RCMmethodol-
ogy is available in the STAR Methods. Here we employed RCM
imaging in humans and various mouse models to study the
role of NKp46 and Ncr1 in controlling tumors and metastases
in vivo. We found that triggering of Ncr1 led to IFN-g secretion
which in turn led to increased fibronectin1 (FN1) expression in
the tumors, affecting their structure and resulting in decreased
metastases.
RESULTS
NK Cells Control B16 Tumors and Metastases in an
Ncr1-Dependent Manner
NKp46 (Ncr1 in mice) is a major NK cell receptor, whose
expression is almost exclusive to NK cells (Delahaye et al.,
2011; Desbois et al., 2012; Morvan and Lanier, 2016). In our
previous studies, we observed that although Ncr1 does not
affect the development of primary tumors growing in the
footpad, it does control the formation of lung metastases
(Glasner et al., 2012a). However, the mechanisms responsible
for these effects are unknown. To investigate whether NK
cells, via Ncr1, can control primary tumor growth in additional
locations (other than the footpad), we inoculated 1 3 106
B16F10.9 melanoma (B16) cells subcutaneously (s.c.) into
the flank of Ncr1+/gfp and Ncr1gfp/gfp mice. In accordance
with our previous findings (Glasner et al., 2012a), no differ-
ences were observed in the flank B16 tumor growth rate be-
tween the various mice groups (Figure 1A). However, similarly
to our previous results, almost half the Ncr1gfp/gfp mice devel-
oped spontaneous peritoneal metastases, compared to only
about 10% in the immune-competent Ncr1+/gfp mice (Fig-
ure 1B). We next injected 10-fold decreasing doses of tumor
cells directly into the peritoneum to generate experimental108 Immunity 48, 107–119, January 16, 2018peritoneal metastases. However, even in the lowest cell
dose, no difference was observed in the Ncr1 ability to control
B16 metastases (Figure 1C, the graph represents mortality
rate following metastases formation). This led us to conclude
that Ncr1 affects metastases formation irrespective of the pri-
mary tumor development, not by restricting tumor growth, but
by other mechanisms.
Tumor Properties Are Similar in the Presence or
Absence of Ncr1
To test whether the developing tumors change the expression of
their unknown Ncr1 ligand following the Ncr1-mediated immune
pressure, we isolated primary tumors that had developed in
Ncr1+/gfp and inNcr1gfp/gfp mice. As themembrane-bound tumor
ligand (or ligands) for Ncr1 and NKp46 are unknown, we stained
the tumor cell lines with Ncr1 Ig fusion proteins and observed
no differences (Figure 1D). Similarly, biochemical properties of
the unknown Ncr1 tumor ligand were identical in the presence
or absence of Ncr1, being insensitive to neuraminidase (NA)
and sensitive to trypsin and proteinase K (Figure 1E). A
CD107a mobilization assay confirmed that all tumors elicited
reduced degranulation in the absence of Ncr1, regardless of
the tumor origin (Figure 1F). We also observed similar levels of
transcripts associated with immune cell populations, such as
NK cells (Figure 1G) and other immune cells (Figures 1H–1L)
within the Ncr1+/gfp and Ncr1gfp/gfp mice tumors. Therefore, we
concluded that primary B16 melanoma tumors develop similarly
in the presence and absence of Ncr1 and that Ncr1 controls B16
metastases.
Ncr1 Control of Metastatic Activity Is Mediated by IFN-g
To test whether the absence of Ncr1 would affect cytokine
secretion, we incubated B16 cells with NK cells isolated from
the Ncr1+/gfp and Ncr1gfp/gfp mice for 12 hr. IFN-g and TNFa
production (pg/mL) by Ncr1+/gfp NK cells was higher compared
to Ncr1gfp/gfp NK cells (Figure 1M). B16 cells express the IFN-g
receptor (IFN-gR) but lack expression of the TNFa receptor
(TNFaR) (Figure 1N), suggesting that IFN-g but not TNFa affect
B16 tumor development and metastases. To demonstrate the
direct Ncr1 involvement in IFN-g secretion, we incubated
Ncr1+/gfp andNcr1gfp/gfp NK cells with B16 targets in the absence
or in the presence of a blocking anti-Ncr1 antibody. IFN-g
secretion was similar in the absence of Ncr1 (Ncr1gfp/gfp) and
following Ncr1 blocking (Figure 1O), indicating that the observed
effect is mediated directly by Ncr1.
We next injected B16 tumors into Ncr1+/gfp and Ncr1gfp/gfp
mice as above, as well as into IFN-g-deficient (Ifng/) and
TNFa-deficient (Tnfa/) mice. While primary B16 tumor growth
was similar in all mice (Figure 1P), more metastases were
observed in the Ifng / and Ncr1gfp/gfp mice (Figure 1Q). These
findings suggest that NK cells’ ability to control metastases is
mediated by IFN-g.
Human Melanomas Exhibited Aggressive Structural
Properties Compared to Nevi, as Revealed by RCM
Imaging
To investigate how Ncr1, via the secretion of IFN-g, modulates
the primary tumors and prevents metastases, we employed
RCM imaging. First, we imaged human melanomas and nevi.
Figure 1. Ncr1 Controls B16 Metastases
(A) Tumor volume after s.c. inoculation of 1 3 106 B16 cells.
(B) Spontaneous metastasis in the same animals presented in (A).
(C) Mice survival after intraperitoneal growth of B16 metastases.
(D and E) FACS staining of B16 cell lines obtained from the tumors originated in Ncr1+/gfp or Ncr1gfp/gfp mice with Ncr1 Ig. Tumors were untreated (D) or treated
with the indicated proteases (E). For (D) and (E), black line histograms represent specific staining. Gray filled histograms are secondary mAb background control
of the untreated cells. Each FACS plot is representative of at least three independent experiments.
(F) CD107a degranulation following 2-hr incubation of B16 cells that developed in Ncr1+/gfp or Ncr1gfp/gfp mice with poly(I:C)-activated NK cells obtained from
Ncr1+/gfp and the Ncr1gfp/gfp mice. Ten mice were used in each group. The experiment was repeated three times. Values are shown as mean ± SEM. *p < 0.05.
(G–L) qRT-PCR presenting relative expression of various immune cell markers in B16 tumors. qRT-PCR assays were performed on triplicates, normalized to
GAPDH and ACTB. Each experiment was repeated three times. Values are shown as mean ± SEM. *p < 0.05. NS, non-significant. In (G), NK cells were detected
using primers targeting exons 1–4 of Ncr1 as in the Ncr1gfp/gfp mice exons 5–7 of Ncr1 were replaced by gfp, whereas exons 1–4 are still present.
(M) IFN-g and TNFa secretion by NK cells derived from Ncr1+/gfp or Ncr1gfp/gfp mice following incubation with B16 cells.
(N) FACS staining of B16 cells. Black line histograms represent specific staining. Gray filled histograms represent background control.
(O) IFN-g secretion by NK cells derived from Ncr1+/gfp or Ncr1gfp/gfp mice following incubation with B16 cells, in the presence or absence of a blocking Ncr1
antibody.
(P) Tumor volume following s.c. flank inoculation of 1 3 106 B16 cells.
(Q) Spontaneous metastasis in the animals presented in (P). At least eight mice were used in each group.
Values are shown as mean ± SEM. *p < 0.05. NS, non-significantFigure S1 shows two human skin lesions that appear similar to
the naked eye (Figures S1A and S1J). However, RCM evaluation,
based on tissue architecture parameters (Pellacani et al., 2007),
enabled the accurate classification of the two lesions as nevus
(Figures S1A–S1I) and melanoma (Figures S1J–S1R). A detailed
description of the analysis is provided in the STAR Methods.
We used RCM to evaluate tissue architecture in 11 human
melanomas compared to 5 nevi and detected significantdifferences in all RCM criteria (summarized in Figures S1S–
S1Z). Thus, RCM can be used to distinguish between human
melanomas and nevi.
Only very few works employ RCM in mice (Chernyavskiy et al.,
2009; Li et al., 2005; Park et al., 2010). To test whether mouse
melanoma tumors would present RCM features similarly to
human melanomas, we performed RCM on B16 tumors and
observed that all human melanoma RCM criteria were alsoImmunity 48, 107–119, January 16, 2018 109
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Figure 2. Ncr1 Edits B16 Structure via IFN-g
(A) An in vivo photo of a B16 tumor taken at time of RCM.
(B–I) In vivo RCM images of B16 tumors.
(J) Tumor volume at time of RCM following s.c. inoculation of 1 3 106 B16 cells.
(K–N) Quantification of the RCM features (described in the STAR Methods) assessed on the tumors presented in (J). Scoring: 1 = least aggressive to 10 = most
aggressive.
(O–R) FACS staining of B16 lines used in (S)–(W). Black line indicates specific staining; gray filled histogram indicates background control.
(S) Tumor volume following s.c. inoculation of 1 3 106 B16 cells.
(T–W) Quantification of RCM features.
For (J)–(N) and (S)–(W), at least eight mice were used in each group. Values are shown asmean ± SEM. *p < 0.05, NS, non-significant. See also Figures S1 and S2.detectable in the B16 mouse tumors (Figures 2A–2I) except
non-edged papillae (Figure 2D) and nucleated cells inside the
papillae (Figure 2I). This is likely because the basal layer is very
thin in mice and dermal papillae are hard to demonstrate. These
findings confirmed RCM as a reliable method to characterize the
structural properties of mouse tumors and that B16 melanomas
are structurally similar to human melanomas.
Ncr1, via IFN-g Secretion, Modulates the Structural
Features of B16 Primary Tumors
To image tumor architecture in vivo, in the absence of Ncr1 and
IFN-g, we inoculatedNcr1+/gfp,Ncr1gfp/gfp, and Ifng/mice with
1 3 106 B16 cells and monitored tumor growth. RCM was per-
formed on tumors of the same volume at two time points: around
1 week and around 2 weeks after tumor inoculation (Figure 2J).110 Immunity 48, 107–119, January 16, 2018RCM analysis revealed significantly worse structural properties
for tumors that developed inNcr1gfp/gfp and Ifng/mice accord-
ing to four RCM criteria (Figures 2K–2N). These criteria have
been previously shown, in humans, to correlate with metastatic
activity (Pellacani et al., 2007; Wisco and Sober, 2012). As these
differences were detected at both time points (Figures 2K–2N
show only the early time point), RCM evaluation was performed
around 1 week after tumor inoculation henceforth. No differ-
ences were observed in two other RCM features (sheet-like
structures and non-homogeneous nests, data not shown).
To corroborate these findings, we evaluated Ncr1+/gfp and
Ncr1gfp/gfp B16 tumors by conventional histology, using hema-
toxylin and eosin (H&E) staining. As seen in Figure S2, and in
agreement with the results observed using RCM, worse
structural properties were detected for Ncr1gfp/gfp B16 tumors
compared to Ncr1+/gfp tumors. (Figure S2A depicts epidermal
invasiveness, quantified in Figure S2B; Figure S2C depicts ulcer-
ation, quantified in Figure S2D; Figure S2E depicts muscle inva-
siveness, quantified in Figure S2F; and Figure S2G depicts lung
metastases, quantified in Figure S2H. Figure S2I shows lower-
magnification images of a whole lung lobe for better clarity.)
To test whether IFN-g secretion alters the structural features of
the B16 tumors directly, we isolated B16 clones expressing
IFN-gR (Figure 2O) or not (Figure 2P). After having verified similar
expression of the unknown Ncr1 ligand (Figures 2Q and 2R), we
injected the tumors into the flanks of Ncr1+/gfp and Ncr1gfp/gfp
mice. Again, RCMwas performed on tumors of the same volume
and developmental stage (Figure 2S). In the absence of IFN-gR,
differences in the four RCM criteria between the groups were
significantly diminished or completely abolished (Figures
2T–2W). Therefore, we concluded that Ncr1-mediated IFN-g is
at least partially responsible for editing the tumor structural
properties and that IFN-g acts directly on the tumor cells to
modulate tumor architecture.
IFN-g Secretion Upregulates FN1, Resulting in a
Structural Organization that Restricts Metastases
Formation
To determine the mechanisms by which Ncr1 edits tumor struc-
ture via IFN-g, we performed RNA sequencing (RNA-seq) on bio-
logical triplicates of IFN-g-treated and untreated B16 cells.
Around 7,000 genes were differentially expressed. As expected,
the vast majority of the differentially expressed genes coded for
proteins participating in antiviral defense, immune response, and
MHC regulation (examples are shown in Figure S3A). As we
observed that Ncr1 affects tumor architecture, we searched for
changes in the expression of structural genes, cell adhesion,
and cellular matrix proteins (Figure S3A). Among the enriched
structural genes, the expression of the extracellular matrix pro-
tein fibronectin1 (FN1) was increased by 24-fold (Figures 3A,
S3A, and S3B). This finding was validated in the presence or
absence of IFN-g, using western blotting (WB) (Figure 3B) and
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) (Figure 3C).
To demonstrate the effect FN1 has on tumor architecture, we
initially tried to overexpress FN1 in B16 and other tumors, using
various methods without success, probably due to its high mo-
lecular weight (440 kDa). Instead, we knocked down (KD)
FN1 in B16 cells using five independent short hairpin RNA
(shRNAs). Figures 3D (WB) and 3E (qRT-PCR) represent one
KD line. Figure S4A shows all control and KD lines generated.
We then inoculated Ncr1+/gfp, Ncr1gfp/gfp, and Ifng/ mice with
the control and FN1 KD B16 cells and monitored tumor growth.
As before, all tumors developed with comparable kinetics (Fig-
ure 3F). Mice inoculated with FN1 KD melanomas exhibited
increased metastasis (Figure 3G). Furthermore, all mice injected
with the FN1 KD tumors showed worse RCM scores (Figures
3H–3K, one representative KD line; and Figures S4B–S4E, all
KD and control lines generated).
To demonstrate that FN1 is expressed in vivo in an Ncr1-de-
pendent manner, we harvested the B16 tumors from Ncr1+/gfp,
Ncr1gfp/gfp, and Ifng / mice and performed FN1 immunofluo-
rescence (IF) staining. The expression of FN1 in tumors obtained
from Ncr1gfp/gfp and Ifng / mice was significantly reduced,compared to theNcr1+/gfp mice (Figure 3L, quantified in 3M [fluo-
rescence intensity] and in 3N [qRT-PCR]). We concluded that
IFN-g mediated the elevated expression of FN1 in the tumors
and that in the absence of IFN-g or FN1, tumors were more
aggressive.
Ncr1 Edits Lewis Lung Carcinoma Tumors via IFN-g and
FN1 and Prevents Metastases
To demonstrate that the Ncr1-dependent structural editing of
tumors is not restricted to a particular cell line or tumor type,
we next used the Lewis lung carcinoma line D122 (Eisenbach
et al., 1983a; Glasner et al., 2012a). D122 tumors expressed
IFN-gR (Figure 4A) and the unknown Ncr1 ligand (Figure 4B).
D122 cells elicited significantly higher IFN-g and TNFa secretion
by NK cells derived from Ncr1+/gfp than Ncr1gfp/gfp mice (Fig-
ure S5A). The IFN-g secretion was abolished in the presence
of anNcr1 blocking antibody (Figure S5B). Like B16, FN1 expres-
sion in D122 cells was significantly elevated following IFN-g
treatment (Figures 4C [WB] and 4D [qRT-PCR]). We generated
control and five independent FN1 KD D122 lines (Figures 4E
and 4F showing one representative KD line and Figure S5C
showing all KD and control lines generated) and inoculated
Ncr1+/gfp, Ncr1gfp/gfp, and Ifng/ mice with a control or FN1
KD D122 tumors.
As the use of RCM imaging is restricted to skin neoplasms, the
D122 tumors were inspected using conventional histopathology,
which was performed on tumors of the same developmental
stage and volume (Figure 4G). Worse structural properties
such as ulceration (Figures 4H–4J), muscle invasiveness (Figures
4K–4M), and metastasis (Figures 4N–4P) were observed in the
tumors grown in Ncr1- or in IFN-g-deficient mice, as well as in
all FN1 KD tumors, irrespective of mouse genotype. In line with
these observations, FN1 expression was significantly reduced
in vivo in the Ncr1gfp/gfp and Ifng/ tumors and in all FN1 KD
D122 tumors (Figure 4Q, one representative FN1 KD line
is shown).
IFN-g Treatment and Ncr1 Overexpression Prevent
Metastases
Based on all of the above, we concluded that IFN-g treatment
should impair metastasis via FN1 induction. To test this, we in-
jected B16-bearing mice with IFN-g. Reduced metastases
formation was observed in all IFN-g-treated mice (Figure 5A),
and RCM properties were significantly improved upon IFN-g
treatment, regardless of the mice genotype (Figures 5B–5E).
We also concluded that overexpressing Ncr1 in NK cells may
offer a therapeutic opportunity to suppress metastasis. To test
this, we used a transgenic mouse that we have generated (Glas-
ner et al., 2017) in which Ncr1 is overexpressed specifically in NK
cells (denoted Ncr1cre Ncr1OE). Inoculation of Ncr1cre Ncr1OE
mice and littermate controls with B16 cells resulted in the com-
parable development of primary tumors (Figure 5F). However,
fewer metastases developed in Ncr1cre Ncr1OE mice, compared
to littermate controls (Figure 5G). RCM features were better in
Ncr1cre Ncr1OE mice as well (Figures 5H–5K), paralleled by
higher levels of Ncr1, IFN-g, and FN1 (Figures 5L–5N).
Throughout the course of this study, we evaluated tumor
volume and metastases in several independent experiments
and in various different mouse groups. To account forImmunity 48, 107–119, January 16, 2018 111
Figure 3. FN1 Mediates the Ncr1-Dependent Structural Editing of B16 Tumors
(A) Volcano plot of relative gene expression in B16 and IFN-g-treated B16 cells, performed on biological triplicates.
(B and D) WB figures are representative of at least three experiments in each assay. Contrast was adjusted to facilitate visualization.
(C and E) qRT-PCR assays were performed on biological triplicates, normalized to GAPDH and ACTB. Each experiment was repeated three times. Values are
shown as mean ± SEM.
(F) Tumors volume following s.c. inoculation of 1 3 106 B16 cells.
(G) Spontaneous metastasis in the animals presented in (F).
(H–K) Quantification of RCM features.
For (F)–(K), at least eight mice were used in each group. Values are shown as mean ± SEM.
(L) Representative IF staining for FN1, quantified in (M).
(N) qRT-PCR for FN1 in B16 tumors.
For (L)–(N), at least six tumors were used in each group. Each experiment was repeated three times. Values are shown as mean ± SEM. *p < 0.05. NS, non-
significant. See also Figures S3 and S4.differences in experimental settings and make an accurate
comparison between all mice groups, we performed an
experiment combining all mice genotypes. We evaluated B16
tumor growth kinetics (Figure S6A) and B16 metastatic
formation (Figure S6B), as well as D122 tumor growth kinetics
(Figure S6C) and metastatic formation (Figure S6D) and
observed that in all cases Ncr1 did not affect primary tumor
growth. In contrast, metastases formation was Ncr1 dependent
as in its absence increased metastases were detected, while
upon its overexpression metastases formation decreased (Fig-
ures S6B and S6D).112 Immunity 48, 107–119, January 16, 2018NK cells and T cells are the main source of IFN-g (Desbois
et al., 2012; Fauriat et al., 2010; Garber, 2016; Morvan and
Lanier, 2016). To demonstrate that NK cell-derived IFN-g is
responsible for the observed effects, we inoculated a control
group (a group including Ncr1+/gfp and the non-transgenic lit-
termates of Ncr1cre Ncr1OE mice), Ncr1gfp/gfp, Ifng/, and
Ncr1cre Ncr1OE mice with B16 tumors. A day prior to tumor
inoculation and every third day after until the time of RCM,
the control mice were injected with either an anti-NK1.1-
depleting antibody (to deplete NK cells) (Figure S6E) or an
anti-CD3-depleting antibody (to deplete T cells) (Figure S6F).
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Figure 4. Ncr1 Edits D122 Structure via IFN-g and FN1
(A and B) FACS staining of D122 cells. Black indicates specific staining; gray indicates background control. Each FACS plot is representative of three independent
experiments.
(C and E) WB figures are representative of three experiments. To facilitate visualization, contrast was adjusted.
(D and F) qRT-PCR assays were performed on triplicates, normalized to GAPDH and ACTB. Each experiment was repeated three times. Values are shown as
mean ± SEM.
(G) Tumor volume following s.c. inoculation of 1 3 106 D122 cells.
(H–P) Hematoxylin and eosin (H&E) staining of paraffin-embedded slides (H, I, K, L, N, O), quantified in (J), (M), and (P).
For (G)–(P), ten mice were used in each group. Values are shown as mean ± SEM.
(Q) qRT-PCR performed on triplicates, normalized to GAPDH and ACTB. Six tumors were used in each group. Values are shown as mean ± SEM. *p < 0.05. NS,
non-significant.
See also Figure S5.Depletion was verified by flow cytometry at different time
points along the experiment. Additionally, a control group
was administered an anti-IFN-g blocking antibody. Mice
were also treated with recombinant IFN-g or left untreated
(Figure 6). Tumors in all mice groups developed at a compara-
ble rate and reached a similar final volume (Figure 6A).
Increased metastases were observed in NK1.1- but not in
CD3-depleted mice (Figure 6B). Moreover, increased metasta-
ses formation was observed also when blocking IFN-g anti-
bodies were used or in Ifng/ mice.
Recombinant IFN-g administration reduced metastases in all
groups (Figure 6B). Likewise, in Ncr1cre Ncr1OE mice, metasta-
ses were significantly reduced (Figure 6B).We next performed RCM evaluation (Figures 6C–6F). Worse
RCM scores were recorded in the absence of Ncr1
(Ncr1gfp/gfp), in the absence of NK cells (anti-NK1.1), or in the
absence of IFN-g (Ifng/, anti-IFN-g). The RCM scores were
improved upon recombinant IFN-g administration or in Ncr1
overexpression (Ncr1cre Ncr1OE) (Figures 6C–6F). These
results indicate NK cells as the main source of IFN-g in the
tumors and NK cell-derived IFN-g as the main player in
modulating tumor structure and preventing metastasis, further
corroborating the critical role of an Ncr1-IFN-g-FN1 axis in
metastases prevention.
FN1 is an important tumor marker and its upregulation in tu-
mors is associated with an epithelial to mesenchymal transitionImmunity 48, 107–119, January 16, 2018 113
Figure 5. IFN-g Administration and Ncr1 Overexpression Improves Mice Survival
(A) Mice were inoculated with B16 tumors, untreated (PBS) or treated with IFN-g every third day from inoculation. Metastases were assessed, in animals bearing
tumors of the same volume, at RCM.
(B–E) RCM features as indicated.
(F) Tumor volume following s.c. inoculation of 2 3 106 B16 cells in littermate controls and Ncr1cre Ncr1OE mice.
(G) Spontaneous metastasis in the animals presented in (F).
(H–K) RCM features as indicated.
For (A)–(K), at least eight animals were used in each group. Values are shown as mean ± SEM. *p < 0.05. NS, non-significant.
(L–N) qRT-PCR performed on B16 tumors. Four controls and five Ncr1cre Ncr1OE tumors were assessed. Values are shown as mean ± SEM.
See also Figure S6.(EMT) profile and to the expression of various EMT-associated
transcription factors (TFs). To investigate how FN1 contributes
to the prevention of metastases, we inoculated Ncr1+/gfp and
Ncr1gfp/gfp mice with B16 and D122 tumors and assessed the
level of various EMT associated TFs at different time points
following tumor inoculation. Figure S7 represents data obtained
from tumors harvested at day 7 (day of RCM) after tumor inocu-
lation. We found increased expression of Keratin (Figure S7A),
N-Cadherin (N-CAD) (Figure S7B), SNAIL (Figure S7C), TWIST
(Figure S7D), and Vimentin (Figure S7E) in the tumors of
Ncr1gfp/gfp compared to Ncr1+/gfp mice. Similar results were
observed for D122 tumors (Figures S7F–S7J). We thus
concluded that an association to a reduced EMT profilemay pro-
vide a partial mechanistic explanation as to the effect by which114 Immunity 48, 107–119, January 16, 2018Ncr1-mediated IFN-g secretion and FN1 induction in tumors pre-
vents metastases in our model.
To extend our findings to humans, we initially stained various
primary melanoma lines obtained from patients for the expres-
sion of IFN-gR (Figure 7A) and the unknown humanNKp46 tumor
ligand (Figure 7B) and observed expression of both in all tested
tumors (Figures 7A and 7B).
We next analyzed datasets from patients of various cancers,
including melanoma and carcinoma. Our analysis demonstrated
that high expression of each of the tested genes alone: Ncr1
(Figure 7C), IFN-g (Figure 7D), IFN-gR (Figure 7E), and FN1 (Fig-
ure 7F) was associatedwith statistically insignificant (Ncr1, IFN-g
IFN-gR, Figures 7C–7E) or statistically significant but small (FN1,
Figure 7F) increase in survival rates. However, the combined
Figure 6. Tumor Development, Metastases, and RCM in the Absence of NK Cells, T Cells, or IFN-g
(A) Tumor volume following s.c. inoculation of 1 3 106 B16 cells.
(B) Spontaneous metastasis in the same animals presented in (A).
(C–F) Quantification of the RCM features (described in STAR Methods) assessed on the tumors presented in (A). Scores: 1 = least aggressive to 10 = most
aggressive. Ten mice were used in each group.
Values are shown as mean ± SEM. *p < 0.05. See also Figures S6 and S7.expression of all genes in primary tumors correlated with signif-
icantly improved recurrence-free survival (Figures 7G and 7H).
DISCUSSION
We (Elboim et al., 2010; Glasner et al., 2012a; Halfteck et al.,
2009) and others (Lakshmikanth et al., 2009) have demonstrated
that NK cells, through the killer receptor NKp46, eliminate
various tumor metastases. However, the mechanisms by which
NKp46 and Ncr1, in mice, influencemetastasis in vivo remain un-
known. Here, we demonstrated that Ncr1 edits the structure of
developing tumors at the level of tissue organization and that
this effect is mediated by the IFN-g-FN1 pathway. We further
demonstrated that after this structural editing, metastases
formation is restricted. We have previously demonstrated that
Ncr1 control of various mouse tumors is mediated by direct
killing rather than cytokine secretion (Glasner et al., 2012a). How-
ever, cytokine measurement in the previous study was per-
formed after 48 and 76 hr of incubation with the targets (in
contrast to 12 hr here), which may have been inappropriate, as
IFN-g and TNFa, the main NK cell cytokines, are secreted very
rapidly and have a very short half-life (Fauriat et al., 2010).
By using RCM in vivo, which as opposed to conventional
histological examination, enables in situ visualization of tumor ar-
chitecture, we were able to determine that the killer receptor
NKp46/Ncr1 affects melanoma tumors by modifying the tumors’
structural properties. This effect was achieved through thesecretion of IFN-g and modulating tumor organization by upre-
gulating the extracellular matrix protein FN1.
Pellacani et al. (2007) used RCM in humans and defined the
aggressivenessof the tumors and their probability tometastasize.
We observed that the B16 melanoma model is very similar to hu-
man melanoma, sharing similar RCM structural properties. In our
RCM evaluation, we found the features of epidermal disarray,
epidermal cellular atypia, dermal-epidermal junction cellular aty-
pia, and dermal epidermal junction cerebriform like cell-clusters
(nests) tobemuchmorepronounced inprimary tumorsdeveloped
in the Ncr1gfp/gfp mice than in those developed in the Ncr1+/gfp
mice. These criteria are particularly important as they are associ-
ated with melanomas thicker than 1 mm in depth (melanoma
thickness is positively correlated to metastatic activity) (Wisco
andSober, 2012). Thismeans that in the absence of Ncr1, tumors
of the same developmental stage and volume feature more
aggressive properties. Indeed, we observed significantly higher
spontaneous metastasis in the absence of Ncr1.
To demonstrate that Ncr1-mediated induction of IFN-g is the
main element playing a role in these effects, we employed
several different methods throughout our study. First, we used
B16 tumors expressing very low levels of IFN-gR or an IFN-g
blocking antibody and observed significant worse metastasis
and structural properties. Next, when depleting NK cells, but
not T cells, we also observed worse metastases formation and
worse structures in the developing tumors. Finally, administra-
tion of recombinant IFN-g reversed these effects.Immunity 48, 107–119, January 16, 2018 115
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Figure 7. NKp46, IFN-g, IFN-gR1, and FN1 Combined Expression in Human Tumors Is Prognostic of Better Survival
(A and B) FACS staining of primary human melanoma lines. Black indicates specific staining and gray indicates background control. The figure represents two
independent stainings.
(C–H) KaplanMeier analysis of survival in patients. Data were taken from the NIH TCGAPANCAN database. Analysis was performed using Xena UCSC. The figure
compares high to low expression of NKp46 (C), IFN-g (D), IFN-gR (E), and FN1 (F) alone or their combined high expression (G, H). Statistics is indicated within
each plot.The results presented here, demonstrating that Ncr1 inhibits
the aggressiveness of the developing tumors via IFN-g, are
particularly important as triggering of Ncr1 may provide the
only source of IFN-g. CD8+ T cells are often inhibited at the sites
of tumors, due to MHC class I downregulation. For example, in
about 67% of human melanomas, MHC class I expression is
downregulated via various mechanisms (Degenhardt et al.,
2010) and thus the secretion of IFN-g from CTLs is prevented.
Furthermore, many human melanomas do not express NKG2D
ligands (Fuertes et al., 2008) and therefore NKG2D, one of the
other major NK cell receptors involved in IFN-g secretion, cannot
be activated. Ncr1 is also expressed by ILCs, although its func-
tion on these cells was shown to be redundant (Rankin et al.,
2016; Satoh-Takayama et al., 2009).
We demonstrated that editing of tumor architecture by Ncr1 is
not restricted to a particular cell line or tumor type, as we showed
that Ncr1 affects the structural properties and metastasis of
D122 in an IFN-g- and FN1-dependent manner. Furthermore,
we were able to generalize our findings to a wide range of human
tumors, by analyzing human patients’ data files using the NIH
TCGA database. Importantly, post hoc analysis of TCGA data
has many caveats and these data should be considered as
hypothesis generating.
Most of the above-mentioned activities of Ncr1 were demon-
strated via the Ncr1gfp/gfp mice (Gazit et al., 2006). To determine116 Immunity 48, 107–119, January 16, 2018the therapeutic potential of our findings, we used a transgenic
mouse in which Ncr1 is overexpressed in NK cells (Ncr1cre
Ncr1OE) (Glasner et al., 2017). In these transgenic mice, tumor
architecture assessed by RCM imaging was found to be better
than in the non-transgenic littermates and led to fewer metasta-
ses formation via the same IFN-g-FN1 pathway. These observa-
tions suggest that overexpression of NKp46 in NK cells may
provide an important perspective for NK cell immunotherapy.
We demonstrated here that Ncr1 impedes metastases via ed-
iting of primary tumors in an IFN-g-FN1-dependent manner.
However, FN1 involvement in tumor development is complex.
FN1 is upregulated in various cancers, including mouse and hu-
man metastatic melanomas (Clark et al., 2000; Kudo-Saito et al.,
2009; Sengupta et al., 2010). FN1 is also an important mesen-
chymal gene associated with a reduction in E-cadherin levels
and increase in N-CAD, Vimentin, and other TFs associated
with EMT and metastasis (Lamouille et al., 2014). On the other
hand, FN1 was found to inhibit tumor growth and metastasis
(Liu et al., 2008; Yi and Ruoslahti, 2001). Failure to deposit stro-
mal FN1 by the tumors was correlated to higher migration, inva-
sion, and metastatic activity (Liu et al., 2008). Reduced FN1
levels were reported at the peripheral margins of invading tumors
and FN1 silencing in some tumors enhanced tumor growth as
well as promoted lungmetastases (Liu et al., 2008). Correspond-
ingly, FN1 expression was higher in poorly metastatic lines
isolated from patients, compared to the higher metastatic ones,
in an immunodeficient mouse xenotransplant metastasis model
(Xu et al., 2008). Clearly, FN1 is a prominent tumor marker impor-
tant for many tumor processes. However, FN1 presence in the
tumors is dynamic, and its expression at certain loci or time
points in tumor development may direct metastatic activity.
Possibly, the association of FN1 expression in tumors with an
increased EMT profile documents the result of a complex inter-
action between the immune system and the tumor.
In summary, our observations indicate that even in the early
pre-metastatic stage, the tumor ‘‘prepares’’ itself to disseminate
and that even at this stage NK cells, via Ncr1-mediated secretion
of IFN-g, attempt to counter these morphological changes. The
finding that Ncr1, through IFN-g and FN1, is involved in modi-
fying tumor organization and consequently restricting metas-
tasis represents a potential avenue for treatment. This paradigm
may pave the way to anti-cancer treatment options and to the
development of drugs specifically aimed at targeting tumor
architecture.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Mice, tumor development and metastasis
B Cells
d METHOD DETAILS
B Fusion proteins, antibodies, and flow cytometry
B CD107a degranulation and cytokine secretion assays
B Evaluation by RCM
B RCM examination of human melanomas
B Quantitative PCR (qRT-PCR) and Western Blot-
ting (WB)
B RNA isolation and library construction for transcrip-
tome analysis
B Processing and Analysis of RNA-Seq Data
B Preparation of cryosections and immunofluorescence
staining
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITY
d ADDITIONAL RESOURCES
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at https://doi.org/10.1016/j.immuni.2017.12.007.
ACKNOWLEDGMENTS
This work was supported by the European Research Council under the Euro-
pean Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant
Agreement number 320473-BacNK. Further support came from the Israel Sci-
ence Foundation, the GIF foundation (to O.M. and B.S.), the ICRF professor-
ship grant, the Helmhultz foundation, and the Rosetrees Trust (all to O.M.).
O.M. is a Crown Professor of Molecular Immunology. A.G. and A.L. were
supported by a grant from the joint research fund of the Hebrew University
and Hadassah Medical Center. J.H.H. is a New York Stem Cell Foundation(NYSCF)-Robertson Investigator. V.S. is supported by SFB-61. L.Z. is sup-
ported by PLBIO INCA 2016. B.S. is supported by the GRK1591 grant and
the Cancer Aid grants #31113557 and #34102500.
AUTHOR CONTRIBUTIONS
A.G. designed and performed the experiments, analyzed the data, and wrote
the manuscript. A.L. performed RCM evaluation and analysis. J.E. and B.I. as-
sisted with performing the experiments. S.O., A.S., T.N., and C.D.E. assisted
with analysis of the data. S.V., J.H.H., and V.S. contributed to generating the
transgenicmice. S.J. contributed reagents. B.S. and L.Z. contributed essential
ideas and discussion. O.M. supervised the work and wrote the manuscript.
DECLARATION OF INTEREST STATEMENT
The authors declare no competing interests.
Received: April 11, 2017
Revised: August 15, 2017
Accepted: December 5, 2017
Published: January 9, 2018; corrected online: January 17, 2018
REFERENCES
Arnold, M., Holterhues, C., Hollestein, L.M., Coebergh, J.W., Nijsten, T.,
Pukkala, E., Holleczek, B., Tryggvado´ttir, L., Comber, H., Bento, M.J., et al.
(2014). Trends in incidence and predictions of cutaneous melanoma across
Europe up to 2015. J. Eur. Acad. Dermatol. Venereol. 28, 1170–1178.
Bar-On, Y., Glasner, A., Meningher, T., Achdout, H., Gur, C., Lankry, D.,
Vitenshtein, A., Meyers, A.F.A., Mandelboim, M., and Mandelboim, O.
(2013). Neuraminidase-mediated, NKp46-dependent immune-evasion mech-
anism of influenza viruses. Cell Rep. 3, 1044–1050.
Bar-On, Y., Seidel, E., Tsukerman, P., Mandelboim, M., and Mandelboim, O.
(2014). Influenza virus uses its neuraminidase protein to evade the recognition
of two activating NK cell receptors. J. Infect. Dis. 210, 410–418.
Breunis, W.B., Tarazona-Santos, E., Chen, R., Kiley, M., Rosenberg, S.A., and
Chanock, S.J. (2008). Influence of cytotoxic T lymphocyte-associated anti-
gen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma
patients with CTLA-4 blockade. J. Immunother. 31, 586–590.
Chaushu, S., Wilensky, A., Gur, C., Shapira, L., Elboim, M., Halftek, G., Polak,
D., Achdout, H., Bachrach, G., and Mandelboim, O. (2012). Direct recognition
of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor
NKp46 aggravates periodontal disease. PLoS Pathog. 8, e1002601.
Chernyavskiy, O., Vannucci, L., Bianchini, P., Difato, F., Saieh, M., and
Kubı´nova´, L. (2009). Imaging of mouse experimental melanoma in vivo and
ex vivo by combination of confocal and nonlinear microscopy. Microsc. Res.
Tech. 72, 411–423.
Clark, E.A., Golub, T.R., Lander, E.S., and Hynes, R.O. (2000). Genomic anal-
ysis of metastasis reveals an essential role for RhoC. Nature 406, 532–535.
Degenhardt, Y., Huang, J., Greshock, J., Horiates, G., Nathanson, K., Yang, X.,
Herlyn, M., and Weber, B. (2010). Distinct MHC gene expression patterns dur-
ing progression of melanoma. Genes Chromosomes Cancer 49, 144–154.
Delahaye, N.F., Rusakiewicz, S., Martins, I., Me´nard, C., Roux, S., Lyonnet, L.,
Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011). Alternatively
spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tu-
mors. Nat. Med. 17, 700–707.
Desbois, M., Rusakiewicz, S., Locher, C., Zitvogel, L., and Chaput, N. (2012).
Natural killer cells in non-hematopoietic malignancies. Front. Immunol. 3, 395.
Diab, M., Vitenshtein, A., Drori, Y., Yamin, R., Danziger, O., Zamostiano, R.,
Mandelboim, M., Bacharach, E., and Mandelboim, O. (2016). Suppression of
human metapneumovirus (HMPV) infection by the innate sensing gene
CEACAM1. Oncotarget 7, 66468–66479.
Diab, M., Glasner, A., Isaacson, B., Bar-On, Y., Drori, Y., Yamin, R.,
Duev-Cohen, A., Danziger, O., Zamostiano, R., Mandelboim, M., et al.
(2017). NK-cell receptors NKp46 and NCR1 control human metapneumovirus
infection. Eur. J. Immunol. 47, 692–703.Immunity 48, 107–119, January 16, 2018 117
Draghi, M., Pashine, A., Sanjanwala, B., Gendzekhadze, K., Cantoni, C.,
Cosman, D., Moretta, A., Valiante, N.M., and Parham, P. (2007). NKp46 and
NKG2D recognition of infected dendritic cells is necessary for NK cell activa-
tion in the human response to influenza infection. J. Immunol. 178, 2688–2698.
Eckelhart, E., Warsch, W., Zebedin, E., Simma, O., Stoiber, D., Kolbe, T.,
R€ulicke, T., Mueller, M., Casanova, E., and Sexl, V. (2011). A novel Ncr1-Cre
mouse reveals the essential role of STAT5 for NK-cell survival and develop-
ment. Blood 117, 1565–1573.
Eisenbach, L., Ramanathan, R., and Nelson, D.L. (1983a). Biochemical studies
of the excitable membrane of paramecium tetraurelia. IX. Antibodies against
ciliary membrane proteins. J. Cell Biol. 97, 1412–1420.
Eisenbach, L., Segal, S., and Feldman, M. (1983b). MHC imbalance and met-
astatic spread in Lewis lung carcinoma clones. Int. J. Cancer 32, 113–120.
Elboim, M., Gazit, R., Gur, C., Ghadially, H., Betser-Cohen, G., and
Mandelboim, O. (2010). Tumor immunoediting by NKp46. J. Immunol. 184,
5637–5644.
Fauriat, C., Long, E.O., Ljunggren, H.G., and Bryceson, Y.T. (2010). Regulation
of human NK-cell cytokine and chemokine production by target cell recogni-
tion. Blood 115, 2167–2176.
Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A.,
O’Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P.B. (2010).
Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J.
Med. 363, 809–819.
Fuertes, M.B., Girart, M.V., Molinero, L.L., Domaica, C.I., Rossi, L.E., Barrio,
M.M., Mordoh, J., Rabinovich, G.A., and Zwirner, N.W. (2008). Intracellular
retention of the NKG2D ligandMHC class I chain-related gene A in humanmel-
anomas confers immune privilege and prevents NK cell-mediated cytotoxicity.
J. Immunol. 180, 4606–4614.
Garber, K. (2016). Natural killer cells blaze into immuno-oncology. Nat.
Biotechnol. 34, 219–220.
Gazit, R., Gruda, R., Elboim, M., Arnon, T.I., Katz, G., Achdout, H., Hanna, J.,
Qimron, U., Landau, G., Greenbaum, E., et al. (2006). Lethal influenza infection
in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7,
517–523.
Ghadially, H., Horani, A., Glasner, A., Elboim, M., Gazit, R., Shoseyov, D., and
Mandelboim, O. (2013). NKp46 regulates allergic responses. Eur. J. Immunol.
43, 3006–3016.
Ghadially, H., Ohana, M., Elboim, M., Gazit, R., Gur, C., Nagler, A., and
Mandelboim, O. (2014). NK cell receptor NKp46 regulates graft-versus-host
disease. Cell Rep. 7, 1809–1814.
Glasner, A., Ghadially, H., Gur, C., Stanietsky, N., Tsukerman, P., Enk, J., and
Mandelboim, O. (2012a). Recognition and prevention of tumor metastasis by
the NK receptor NKp46/NCR1. J. Immunol. 188, 2509–2515.
Glasner, A., Zurunic, A., Meningher, T., Lenac Rovis, T., Tsukerman, P.,
Bar-On, Y., Yamin, R., Meyers, A.F., Mandeboim, M., Jonjic, S., and
Mandelboim, O. (2012b). Elucidating the mechanisms of influenza virus recog-
nition by Ncr1. PLoS ONE 7, e36837.
Glasner, A., Roth, Z., Varvak, A., Miletic, A., Isaacson, B., Bar-On, Y., Jonjic, S.,
Khalaila, I., and Mandelboim, O. (2015a). Identification of putative novel O-gly-
cosylations in the NK killer receptor Ncr1 essential for its activity. Cell Discov.
1, 15036.
Glasner, A., Simic, H., Miklic, K., Roth, Z., Berhani, O., Khalaila, I., Jonjic, S.,
and Mandelboim, O. (2015b). Expression, function, and molecular properties
of the killer receptor Ncr1-Noe´. J. Immunol. 195, 3959–3969.
Glasner, A., Isaacson, B., Viukov, S., Neuman, T., Friedman, N., Mandelboim,
M., Sexl, V., Hanna, J.H., andMandelboim, O. (2017). Increased NK cell immu-
nity in a transgenic mouse model of NKp46 overexpression. Sci. Rep.
7, 13090.
Gur, C., Porgador, A., Elboim, M., Gazit, R., Mizrahi, S., Stern-Ginossar, N.,
Achdout, H., Ghadially, H., Dor, Y., Nir, T., et al. (2010). The activating receptor
NKp46 is essential for the development of type 1 diabetes. Nat. Immunol. 11,
121–128.
Gur, C., Enk, J., Kassem, S.A., Suissa, Y., Magenheim, J., Stolovich-Rain, M.,
Nir, T., Achdout, H., Glaser, B., Shapiro, J., et al. (2011). Recognition and killing118 Immunity 48, 107–119, January 16, 2018of human and murine pancreatic beta cells by the NK receptor NKp46.
J. Immunol. 187, 3096–3103.
Gur, C., Doron, S., Kfir-Erenfeld, S., Horwitz, E., Abu-Tair, L., Safadi, R., and
Mandelboim, O. (2012). NKp46-mediated killing of human and mouse hepatic
stellate cells attenuates liver fibrosis. Gut 61, 885–893.
Gur, C., Coppenhagen-Glazer, S., Rosenberg, S., Yamin, R., Enk, J., Glasner,
A., Bar-On, Y., Fleissig, O., Naor, R., Abed, J., et al. (2013a). Natural killer
cell-mediated host defense against uropathogenic E. coli is counteracted by
bacterial hemolysinA-dependent killing of NK cells. Cell Host Microbe 14,
664–674.
Gur, C., Enk, J., Weitman, E., Bachar, E., Suissa, Y., Cohen, G., Schyr, R.B.,
Sabanay, H., Horwitz, E., Glaser, B., et al. (2013b). The expression of the
beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated
in type 2 diabetes. PLoS ONE 8, e74033.
Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J.,
Bar-On, Y., Stanietsky-Kaynan, N., Coppenhagen-Glazer, S., et al. (2015).
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory
receptor TIGIT protects tumors from immune cell attack. Immunity 42,
344–355.
Guy, G.P., and Ekwueme, D.U. (2011). Years of potential life lost and indirect
costs of melanoma and non-melanoma skin cancer: a systematic review of
the literature. Pharmacoeconomics 29, 863–874.
Halfteck, G.G., Elboim, M., Gur, C., Achdout, H., Ghadially, H., and
Mandelboim, O. (2009). Enhanced in vivo growth of lymphoma tumors in the
absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 182,
2221–2230.
Jarahian, M., Watzl, C., Fournier, P., Arnold, A., Djandji, D., Zahedi, S.,
Cerwenka, A., Paschen, A., Schirrmacher, V., and Momburg, F. (2009).
Activation of natural killer cells by newcastle disease virus hemagglutinin-neur-
aminidase. J. Virol. 83, 8108–8121.
Jarahian, M., Fiedler, M., Cohnen, A., Djandji, D., H€ammerling, G.J., Gati, C.,
Cerwenka, A., Turner, P.C., Moyer, R.W., Watzl, C., et al. (2011). Modulation
of NKp30- and NKp46-mediated natural killer cell responses by poxviral hem-
agglutinin. PLoS Pathog. 7, e1002195.
Koch, J., Steinle, A., Watzl, C., and Mandelboim, O. (2013). Activating natural
cytotoxicity receptors of natural killer cells in cancer and infection. Trends
Immunol. 34, 182–191.
Kudo-Saito, C., Shirako, H., Takeuchi, T., and Kawakami, Y. (2009). Cancer
metastasis is accelerated through immunosuppression during Snail-induced
EMT of cancer cells. Cancer Cell 15, 195–206.
Lakshmikanth, T., Burke, S., Ali, T.H., Kimpfler, S., Ursini, F., Ruggeri, L.,
Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009). NCRs and
DNAM-1 mediate NK cell recognition and lysis of human and mouse mela-
noma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251–1263.
Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithe-
lial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196.
Li, Y., Gonzalez, S., Terwey, T.H., Wolchok, J., Li, Y., Aranda, I., Toledo-Crow,
R., and Halpern, A.C. (2005). Dual mode reflectance and fluorescence
confocal laser scanningmicroscopy for in vivo imagingmelanoma progression
in murine skin. J. Invest. Dermatol. 125, 798–804.
Liu, W., Cheng, S., Asa, S.L., and Ezzat, S. (2008). The melanoma-associated
antigen A3 mediates fibronectin-controlled cancer progression and metas-
tasis. Cancer Res. 68, 8104–8112.
Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T.I., Bushkin, Y.,
Davis, D.M., Strominger, J.L., Yewdell, J.W., and Porgador, A. (2001).
Recognition of haemagglutinins on virus-infected cells by NKp46 activates
lysis by human NK cells. Nature 409, 1055–1060.
Morvan, M.G., and Lanier, L.L. (2016). NK cells and cancer: you can teach
innate cells new tricks. Nat. Rev. Cancer 16, 7–19.
Parakh, S., Park, J.J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M.,
Rowe, C., Wong, A., McArthur, G., et al. (2017). Efficacy of anti-PD-1 therapy
in patients with melanoma brain metastases. Br. J. Cancer 116, 1558–1563.
Park, J., Mroz, P., Hamblin, M.R., and Yaroslavsky, A.N. (2010). Dye-enhanced
multimodal confocal microscopy for noninvasive detection of skin cancers in
mouse models. J. Biomed. Opt. 15, 026023.
Pellacani, G., Guitera, P., Longo, C., Avramidis, M., Seidenari, S., andMenzies,
S. (2007). The impact of in vivo reflectance confocal microscopy for the diag-
nostic accuracy of melanoma and equivocal melanocytic lesions. J. Invest.
Dermatol. 127, 2759–2765.
Porgador, A., Feldman, M., and Eisenbach, L. (1989). H-2Kb transfection of
B16 melanoma cells results in reduced tumourigenicity and metastatic
competence. J. Immunogenet. 16, 291–303.
Rankin, L.C., Girard-Madoux, M.J., Seillet, C., Mielke, L.A., Kerdiles, Y., Fenis,
A., Wieduwild, E., Putoczki, T., Mondot, S., Lantz, O., et al. (2016).
Complementarity and redundancy of IL-22-producing innate lymphoid cells.
Nat. Immunol. 17, 179–186.
Satoh-Takayama, N., Dumoutier, L., Lesjean-Pottier, S., Ribeiro, V.S.,
Mandelboim, O., Renauld, J.C., Vosshenrich, C.A., and Di Santo, J.P.
(2009). The natural cytotoxicity receptor NKp46 is dispensable for IL-22-medi-
ated innate intestinal immune defense against Citrobacter rodentium.
J. Immunol. 183, 6579–6587.
Seidel, E., Glasner, A., andMandelboim, O. (2012). Virus-mediated inhibition of
natural cytotoxicity receptor recognition. Cell. Mol. Life Sci. 69, 3911–3920.Sengupta, S., Nandi, S., Hindi, E.S., Wainwright, D.A., Han, Y., and Lesniak,
M.S. (2010). Short hairpin RNA-mediated fibronectin knockdown delays tumor
growth in a mouse glioma model. Neoplasia 12, 837–847.
Sheppard, S., Triulzi, C., Ardolino, M., Serna, D., Zhang, L., Raulet, D.H., and
Guerra, N. (2013). Characterization of a novel NKG2D and NKp46 double-
mutant mouse reveals subtle variations in the NK cell repertoire. Blood 121,
5025–5033.
Vitenshtein, A., Charpak-Amikam, Y., Yamin, R., Bauman, Y., Isaacson, B.,
Stein, N., Berhani, O., Dassa, L., Gamliel, M., Gur, C., et al. (2016). NK cell
recognition of Candida glabrata through binding of NKp46 and NCR1 to fungal
ligands Epa1, Epa6, and Epa7. Cell Host Microbe 20, 527–534.
Wensveen, F.M., Jelencic, V., Valentic, S., Sestan, M., Wensveen, T.T.,
Theurich, S., Glasner, A., Mendrila, D., Stimac, D., Wunderlich, F.T., et al.
(2015). NK cells link obesity-induced adipose stress to inflammation and insu-
lin resistance. Nat. Immunol. 16, 376–385.
Wisco, O.J., and Sober, A.J. (2012). Prognostic factors for melanoma.
Dermatol. Clin. 30, 469–485.
Xu, L., Shen, S.S., Hoshida, Y., Subramanian, A., Ross, K., Brunet, J.P.,
Wagner, S.N., Ramaswamy, S., Mesirov, J.P., and Hynes, R.O. (2008). Gene
expression changes in an animal melanoma model correlate with aggressive-
ness of human melanoma metastases. Mol. Cancer Res. 6, 760–769.
Yi, M., and Ruoslahti, E. (2001). A fibronectin fragment inhibits tumor growth,
angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA 98, 620–624.Immunity 48, 107–119, January 16, 2018 119
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Alexa Fluor 647 conjugated goat anti human IgG, F(ab’)2 JacksonImmunoResearch
Laboratories, West Grove, PA
Cat#109-606-097
Alexa Fluor 647 streptavidin JacksonImmunoResearch
Laboratories, West Grove, PA
Cat#016-600-084
Alexa Fluor 647 conjugated goat anti mouse IgG (H+L) JacksonImmunoResearch
Laboratories, West Grove, PA
Cat#115-095-062
Biotin anti mouse CD119 (IFN-gR a chain), Bioledgend (Enco Israel) Cat#112803
Purified anti mouse TNFa Bioledgend (Enco Israel) Cat#506301
Polyclonal FN1 abcam (Zotal, Isreal) Cat#ab2413
Anti mNcr1.15 Prof. Stipan Jonjic (University of
Rijeka, B. Branchetta, Rijeka, Croatia)
Glasner et al. (2015a, 2015b)
InVivoMAb anti mouse NK1.1, clone PK136. Bio X Cell Cat#BE0036-5
InVivoMAb anti mouse CD3ε, clone 145-2C11 Bio X Cell Cat#BE0001-1
InVivoMAb anti mouse IFN-g, clone XMG1.2 Bio X Cell Cat#BE0055-25
APC anti mouse CD107a (LAMP-1) Biotest (Enco Israel) Cat#121614
Chemicals, Peptides, and Recombinant Proteins
Proteinase K Sigma-Aldrich (Rehovot, Israel) Cat#P2308
Neuraminidase Mercury, Israel Cat#MBS480716250Ml
Recombinant IFN-g (carrier free) Bioledgend (Enco Israel) Cat#575302
Critical Commercial Assays
TrueSeq RNA V2 kit Illumina Cat#RS-122-2001
/2
EasySep mouse NKcell isolation kit STEMCELL (Enco Israel) Cat#19855
Deposited Data
RNA seq of IFN-g treated and untreated B16 cells This paper GEO: GSE106390
Experimental Models: Cell Lines
B16F10.9 Prof. Eisenbach (The Weizmann
Institute of Science, Rehovot, Israel)
Porgador et al. (1989)
D122 Prof. Eisenbach (The Weizmann
Institute of Science, Rehovot, Israel)
Eisenbach et al. (1983b)
Experimental Models: Organisms/Strains
IFN-g/ mice, B6.129S7-IFN-gtm1Ts/J the Jackson Laboratory (Bar Harbor, ME) Cat#002287
TNFa/ mice, B6;129S-Tnftm1Gkl/J the Jackson Laboratory (Bar Harbor, ME) Cat#003008
Ncr1cre Ncr1OE This paper N/A
Ncr1+/gfp, Ncr1gfp/gfp Gazit et al. (2006) Cat#022739CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ofer
Mandelboim (oferm@ekmd.huji.ac.il).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice, tumor development and metastasis
All experiments were performed using 6–8 weeks old C57BL/6 male and female mice. The generation of the Ncr1gfp/gfp mouse was
described previously (Gazit et al., 2006). Ncr1+/gfp and Ncr1gfp/gfp mice possess normal numbers of NK cells and their NK celle1 Immunity 48, 107–119.e1–e4, January 16, 2018
education is normal (Gazit et al., 2006; Glasner et al., 2015b; Satoh-Takayama et al., 2009; Sheppard et al., 2013) IFN-g/ and
TNFa/ mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Ncr1cre Ncr1OE mice were generated by crossing
Ncr1cre (Eckelhart et al., 2011) and Ncr1 Rosa Stop mice (Glasner et al., 2017). All mice were housed under SPF conditions, normal
light/dark cycles and 22+/2C. All experiments were performed in a specific pathogen free unit of the Hebrew University Medical
School (Ein-Kerem, Jerusalem) in accordance with the guidelines of the ethics committee. Mice of different genotypes (or littermates
when relevant) were allocated randomly to the different experimental groups in each experiment. Peritoneal tumor growth was as-
sessed by injecting 10-fold decreasing dose of B16 cells into the peritoneal cavity of Ncr1+/gfp and Ncr1gfp/gfp mice. The mice were
monitored daily, and sacrificed at any indication of illness such as bristled fur, difficult breathing, tremor or any other sign of disease.
The sacrificed mice chest and peritoneal cavities were explored post-mortem, and the presence of tumors was visually verified. Any
surviving mice were sacrificed at day 120 post tumor inoculation, their chest cavities were explored and the absence of metastases
was verified by visual inspection. For RCM evaluation, histopathological analysis and spontaneous metastases assessment, B16 or
D122 cells were subcutaneously (s.c.) injected into the flank and tumors weremonitored daily. RCM evaluation and histopathological
analysis were always conducted in a blinded manner, where the evaluating physician inspected randomly-numbered coded image
files or numbered H&E stained slides with no indication of the animal’s genotype.
In all experiments, by the time tumors reached a maximal volume of 1000mm3, all mice were sacrificed and the presence of me-
tastases in the peritoneum and chest cavity was assessed visually. No differences were observed between the variousmice groups in
their general health at baseline.
Cells
Male B16F10.9 (B16) cells and D122 Lewis Lung Carcinoma (D122) were kindly provided by Prof. Eisenbach (TheWeizmann Institute
of Science, Rehovot, Israel). Cells were authenticated. Cells were grown in DMEM supplemented with 1% L-glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, 1% pen strep and 5% FCS. Cells were grown in 37C, 5% CO2. To obtain cell lines
from the B16 tumors of Ncr1+/gfp and Ncr1gfp/gfp mice, tissue samples were treated with trypsin, washed and placed in culture.
Two days later, tissues were removed and cells were grown in supplemented DMEM. All cells were stained for the expression of
Ncr1 ligand within one week in culture at most. PK treatment included 20 min incubation of the cells with 10ml PK (20 mg/ml);
Sigma-Aldrich, Rehovot, Israel) in 37C, 5% CO2.
METHOD DETAILS
Fusion proteins, antibodies, and flow cytometry
The Ncr1 Ig and NKp46 Ig fusion proteins were generated by PCR amplification of mouse and human cDNA, and cloned in framewith
human IgG. The resulting constructs were transduced into HEK293T cells. Treatment of fusion proteins with NA included incubation
with 10ug NA (Mercury, Israel) for 2 hours at 37C. The integrity of the treated fusion proteins was assessed by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS-PAGE) gel analysis. The staining of all cell lines by fusion proteins was visualized using
an Alexa Fluor 647 conjugated Goat Anti-Human IgG, F(ab’)2 (JacksonImmunoResearch Laboratories, West Grove, PA). To assess
IFN-gR, biotin anti-mouseCD119 (IFN-gR a chain), (BioLegend) was used. To asses TNFaR, purified anti-mouse TNFaAntibody (Bio-
Legend) was used. IFN-gR and TNFaR staining was visualized using Alexa Fluor 647 Streptavidin, or Alexa Fluor 647 conjugated
Goat Anti-Mouse IgG (H+L) secondary antibodies (JacksonImmunoResearch Laboratories, West Grove, PA), respectively.
mNcr1.15was used as a blocking anti-Ncr1 antibody. Polyclonal FN1 antibodies (Abcam) were used for WB and IF staining. For
the treatment of B16 and D122 cells with IFN-g, cells 1x106 cells were seeded in triplicates and supplemented with recombinant
mouse IFN-g (carrier free) (BioLegend) containing medium (50mg /ml) for 24 hours. For in vivo depletion of NK1.1 expressing cells,
mice were injected i.p every third day with 25mg of InVivoMAb anti mouse NK1.1, clone PK136 (Bio X Cell). For in vivo depletion
of CD3 expressing cells, mice were injected every third day with 200mg of InVivoMAb anti mouse CD3ε, clone 145-2C11 (Bio X
Cell). For in vivo blocking of IFN-g, mice were injected i.p. every third day with 200mg of InVivoMAb anti-mouse IFN-g, clone
XMG1.2 (Bio X Cell). For recombinant IFN-g treatment, mice were injected every third day with 100mg of IFN-g (carrier free)
(BioLegend).
CD107a degranulation and cytokine secretion assays
Mice were injected intraperitoneally (i.p.) with 200mg Poly I:C (Sigma Aldrich Israel) and PBLs were harvested 18 hours later. NK cells
were isolated using the EasySepTmouse NK cell enrichment kit and co-incubated at 37C at the indicated ratios, with the target cells
in the presence of an APC conjugated anti-mouse CD107a (LAMP-1) (Biotest (121614) for two hours and CD107a levels on the
GFP-positive NK cells were determined by flow cytometry. To assess IFN-g and TNFa secretion, NK cells were isolated from
Poly I:C activated PBLs using the EasySepTM mouse NK cell enrichment kit and incubated with B16 cells at 37C and 5% CO2.
Then, supernatants were collected and cytokines levels were measured using standard ELISA.
Evaluation by RCM
In vivo RCM was performed using a reflectance confocal microscope (Vivascope 1500, Caliber I.D. Inc., Rochester, NY, USA). The
system uses an 830-nm wavelength diode laser. The laser beam is directed by a dichromatic mirror (beam splitter) toward a pair of
mirrors that perform horizontal scanning of the selected skin area. The laser beam then passes through themicroscope objective lensImmunity 48, 107–119.e1–e4, January 16, 2018 e2
and enters the skin where it can encounter tissue structures of various reflective properties. Next, backscattered light from the tissue
re-enters the objective lens and the dichromatic mirror that focuses it onto a gating pinhole. A photomultiplier detector measures the
light that enters via the pinhole and produces optical images. The system provides high optical resolution (horizontal axis 2.0mm;
vertical axis 5.0mm) to a penetration depth of about 250mm.
Ultrasound gel was used as an immersionmedium (refractive index 1.33). A set of sequential horizontal RCMoptical sections (each
500um x 500um in area) was acquired at 1.0um intervals from the corneal skin layer (skin surface) to the hypodermis (fatty layer under
the skin). For each tumor, we obtained at least 20 images, optically sectioning through the corneal layer, granular and spinous layers,
basal layer / epidermal-dermal junction, upper dermis, lower dermis and hypodermis. RCM features of melanoma were recognized
and quantified by either counting the number of times they appear in a 1mm2 area or by grading them on a 1-10 scale (1 = least
aggressive to 10 = most aggressive). Evaluator of the above features was blinded to the genotype of the mice and the tumors.
RCM examination of human melanomas
Figure S1A-R shows two human pigmented skin lesions that appear macroscopically similar, displaying slight asymmetry, minor
border irregularities and diameter larger than 0.8cm (S1A and S1J). In routine clinical practice, both lesions would have been surgi-
cally removed to rule the possible diagnosis of melanoma. However, RCM evaluation, based on tissue architectural parameters as
defined by (Pellacani et al., 2007), enables the differentiation of the two samples into benign nevus (Figure S1A) and malignant mel-
anoma (Figure S1J). The structural parameters tested include ‘epidermal disarray’, which refers to the disruption of the normal
pattern of keratinocytes of the granular and spinous (suprabasal) layers of the epidermis. A nevus (Figure S1B) usually presents
regular organization and density of keratinocytes at the suprabasal layers, forming a honeycomb or cobblestone pattern (or a com-
bination of both); in contrast, melanoma (Figure S1K) often displays an irregular pattern of suprabasal epidermal keratinocytes with
uneven distribution of the bright cells. Infiltration of the suprabasal epidermis by melanocytes is termed ‘pagetoid spread of mela-
nocytes’; the cellular outline of these neoplastic melanocytes can be either dendritic (appearing as bright nucleated cells with
branch-like extensions) or round (appearing as round bright nucleated cells with a dark nucleus). Melanocytes in pagetoid pattern
infiltrating the suprabasal epidermal layers are commonly seen in melanomas (Figure S1L red arrows) and very rarely in nevi (Fig-
ure S1C). ‘Pagetoid cellular atypia’ in the epidermis is a term that refers to variability in the shape and size of the bright melanocytes;
it is another criterion very rarely observed in nevi (Figure S1C), yet noticeable in melanomas (Figure S1L). At the level of the basal layer
of the epidermis, normal skin of dark-skin individuals and nevi display a pattern termed ‘edged dermal papillae’, denoting regular
rimming of the dermal papillae by small, bright basal keratinocytes (Figure S1D); the disruption of this normal structure by melanoma
creates a pattern termed ‘non-edged dermal papillae’ (Figure S1M -red circles). At the level of the basal layer of the epidermis, cellular
atypia of melanocytes is determined by the presence of large bright cells (at least twice as large as a normal basal keratinocyte), that
also show pleomorphism (variability in their size and shape). Cellular atypia of melanocytes is infrequent and relatively minor in nevi
(Figure S1E) compared to melanomas (Figure S1N). ‘Sheet-like structures’ denotes a proliferation of closely-set bright melanocytes
within the epidermal-dermal junction, obscuring and eliminating the normal architecture of the junction (that typically includes visible
dermal papillae). This phenomenon is observed almost exclusively in melanomas (Figure S1F) and very infrequently in nevi
(Figure S1O). While nevi usually exhibit ‘homogeneous clusters of melanocytes’ (red circles) within the upper dermis (Fig.S1H),
‘cerebriform’ (Figure S1P) and ‘non-homogeneous’ (Figure S1Q) aggregates (red circles) appear in melanomas. ‘Bright round cells’
or ‘triangular cells’ with well-demarcated dark nucleus (red circle) infiltrate the dermal papilla much more often in melanomas
(Figure S1R) than in nevi (Figure S1I). Figure S1S-Z represents the assessment of the RCM criteria in five nevi and eleven confirmed
human melanomas. RCM evaluation was performed blindly.
Quantitative PCR (qRT-PCR) and Western Blotting (WB)
mRNA was isolated using R1055 Quick-RNA MiniPrep Kit (Eisenberg bros, Israel) and reversetranscribed to cDNA using M-MLV
Reverse Transcriptase 28025-013 (Invitrogen, ThermoFisher Scientific) Quantitative PCR (qRT-PCR) was performed with Platinum
SYBR Green qPCR SuperMix-UDG w/ROX (ThermoFisher Scientific) in triplicates, normalized to GAPDH and ACTB. For WB, cell
lysates were run on 10% SDS-PAGE gel, transferred to a nitrocellulose membrane (Tamar Laboratory Supplies), and stained with
GAPDH or Polyclonal FN1 antibody (Abcam, ab2413).
RNA isolation and library construction for transcriptome analysis
Ten to the sixth cells from each of three replicates of B16 or IFN-g treated B16 cells were lysed and frozen in 80. The libraries were
constructed using TrueSeq RNA V2 kit by Illumina.
Processing and Analysis of RNA-Seq Data
Trimming and filtering of raw reads: Raw reads (fastq files) were inspected for quality issues with FastQC (v0.11.2, http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). According to the FastQC report, reads were quality-trimmed at both ends, using
in-house Perl scripts, with a quality threshold of 33. In short, the scripts use a sliding window of 5 bases from the read’s end and trim
one base at a time until the average quality of the window passes the given threshold. Reads that became sorter than 15 bases were
discarded.
Mapping and differential expression analysis: The processed fastq files were mapped to the mouse transcriptome and
genome using TopHat (v2.0.11). The genome version was GRCm38, with annotations from Ensembl release 76. Mapping allowede3 Immunity 48, 107–119.e1–e4, January 16, 2018
up to 5 mismatches per read, a maximum gap of 5 bases, and a total edit distance of 10 (full command: tophat -G genes.gtf -N
5–read-gap-length 5–read-edit-dist 10–segment-length 20 –coverage-search–read-realign-edit-dist 8–b2-i S,1,0.75–b2-mp
3,1–b2-score-min L,-0.5,-0.5 genome processed.fastq). Quantification, normalization and differential expression were done with
the Cufflinks package (v2.2.1). Quantification was done with cuffquant, using the genome bias correction (-b parameter) and the
multi-mapped reads assignment algorithm (-u parameter). Normalization was done with cuffnorm (using output format of Cuffdiff)
and results were visualized in R, using the cummeRbund package (version 2.8.2) and in-house R scripts. Counts and FPKM distri-
butions, as well as MDS analysis, were used for comparing global expression between samples, outliers evaluation (none were
found) and background expression level estimation. Differential expression was calculated with cuffdiff, using a count threshold
(-c parameter) of at least 4 for statistical significance testing. Samples were assigned a condition (-L parameter) and the three rep-
licates of INF-treated cells were compared to the three replicates of the non-treated ones. Gene-level cuffdiff output was combined
with gene details (such as symbol, Entrez accession, etc.) taken from the results of a BioMart query (Ensembl, release 76). Signifi-
cantly differentially expressed genes were defined as ones with at least 0.5 FPKM level of expression in at least one of the conditions
and a q-value less than 0.05. Differential expression results were visualized in R using the cummeRbund package. Pathway analysis
was performed using Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity). http://www.
illumina.com/products/truseq_rna_sample_prep_kit_v2.html).
Preparation of cryosections and immunofluorescence staining
Tumors were harvested, placed in 30% sucrose solution overnight and then fixed in OCT and frozen in liquid nitrogen. 10 mm slides
were cut using Leica CM1950 Clinical Cryostat (Leica Biosystems Nussloch GmbH) and slides were mounted and frozen in 80C.
For immunoflourescent (IF) staining, slides were fixated inmethanol at20C for 1h, washed twice in PBS and placed in PBSwith 1%
Triton X-100 (Octyl Phenol Ethoxylate; J.T.Baker). The slides were blocked with CAS-Block Histochemical Reagent 008120
(ThermoFisher Scientific) for 4h at RT. Anti FN1 (Abcam ab2413) was diluted 1:200 in CAS-block and applied to the slides ON at
4C. Secondary mAb and DAPI were applied following washes with PBS and IF images were captured on an Olympus Fluoview
FV1000 confocal microscope 400 or 80 fold magnification. IF staining was performed on tumors harvested from mice, at least
five tumors were used in each experiment, and each experiment was repeated at least three times. Representative figures are pre-
sented at the indicated magnification. The FV10-ASW version 03.00.01.15 software was used to assess fluorescence intensity.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of Variance (ANOVA) or Student’s t test were used to identify significant group differences. To assess survival, the Kaplan
Meir model was used followed by the log rank test. p < 0.05 was considered significant in all studies, indicated by*. NS; Non-
Significant. Details may be found in each figure legend.
DATA AND SOFTWARE AVAILABILITY
Untreated and IFN-g treated B16 cells RNA seq data are available at the NCBI GEO under accession number GSE106390.
ADDITIONAL RESOURCES
TCGA data analysis was performed using UCSC, Xena, Description: URL: http://xena.ucsc.edu/.Immunity 48, 107–119.e1–e4, January 16, 2018 e4
